The effect of polymorphisms in startle-related genes on anxiety symptom severity

J Psychiatr Res. 2020 Jun:125:144-151. doi: 10.1016/j.jpsychires.2020.03.019. Epub 2020 Apr 3.

Abstract

Given the limited effectiveness of treatments for pathological anxiety, there is a pressing need to identify genetic markers that can aid the precise selection of treatments and optimize treatment response. Anxiety and startle response levels demonstrate a direct relationship, and previous literature suggests that exaggerated startle reactivity may serve as an endophenotype of pathological anxiety. In addition, genetic variants related to startle reactivity may play a role in the etiology of pathological anxiety. In the current study, we selected 22 single nucleotide polymorphisms (SNPs) related to startle reactivity in the literature, and examined their association with anxiety symptom severity across psychiatric disorders (n = 508), and in a subset of patients with an anxiety disorder (n = 298). Overall, none of the SNPs pass correction for multiple independent tests. However, across psychiatric patients, rs6323 from the monoamine oxidase A (MAOA) gene and rs324981 from the neuropeptide S receptor 1 (NPSR1) gene were nominally associated with baseline anxiety symptom severity (p = 0.017, 0.023). These preliminary findings provide support for investigating startle-related genetic variants to identify biomarkers of anxiety symptom severity.

Keywords: Anxiety; Endophenotypes; Genetics; Single nucleotide polymorphisms; Startle response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anxiety Disorders*
  • Anxiety* / genetics
  • Endophenotypes
  • Humans
  • Polymorphism, Single Nucleotide / genetics
  • Receptors, G-Protein-Coupled / genetics
  • Reflex, Startle / genetics

Substances

  • NPSR1 protein, human
  • Receptors, G-Protein-Coupled

Grants and funding